Heidelberg Pharma AG (WL6) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
63
About the Report
About the Report
Summary
Heidelberg Pharma AG (Heidelberg Pharma) formerly, Wilex AG is a biopharmaceutical company. The company develops therapeutic and diagnostic product candidates for the treatment and specific detection of various cancers. Heidelberg Pharma's pipeline products are focused on treating multiple myeloma, prostate cancer, hematological cancers, metastatic pancreatic cancers, leukemia, non- metastatic ccRCC, kidney cancers and solid tumors. Through its subsidiaries it also provides preclinical contract research services and an antibody drug conjugate (ADC) technology platform. Heidelberg Pharma is headquartered in Ladenburg, Germany.
Heidelberg Pharma AG (WL6)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Heidelberg Pharma AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heidelberg Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Telix Pharma Enters into Licensing Agreement with Wilex 12
Magenta Therapeutics Enters into Multi-Target Research Agreement with Heidelberg Pharma 13
Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 14
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 15
Heidelberg Pharma Enters into Agreement with Celonic 16
Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 17
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 18
Licensing Agreements 19
Magenta Therapeutics Enters into Licensing Agreement with Heidelberg Pharma 19
Heidelberg Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 20
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 21
RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 22
Wilex Enters Into Licensing Agreement With Link Health For Mesupron 23
Equity Offering 24
Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 24
Wilex Raises USD5.4 Million in Rights Offering of Shares 25
Wilex to Raise USD4.7 Million in Rights Offering of Shares 26
Wilex Raises USD1.81 Million in Private Placement of Shares 27
Wilex Raises USD0.86 Million in Rights Offering of Shares 28
Wilex Raises USD4.4 Million in Right Issue of Shares 29
Wilex Completes Private Placement Of Shares For USD 12.4 Million 30
Wilex Completes Rights Offering Of Shares For USD 7.8 Million 31
Wilex Completes Rights Offering Of Shares For USD 12.6 Million 32
Debt Offering 33
Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 33
Asset Transactions 34
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 34
Heidelberg Pharma AG-Key Competitors 35
Heidelberg Pharma AG-Key Employees 36
Heidelberg Pharma AG-Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Oct 11, 2018: Heidelberg Pharma AG: Interim management statement on the first nine months of 2018 38
Jul 12, 2018: Heidelberg Pharma reports on first half -year 40
Apr 12, 2018: Heidelberg Pharma: Interim Management Statement on the First Three Months of 2018 42
Mar 22, 2018: Heidelberg Pharma announces financial figures for fiscal year 2017 and provides business update 44
Oct 09, 2017: WILEX: Interim management statement for the first nine months of 2017 47
Jul 13, 2017: WILEX reports on first half-year 50
Apr 12, 2017: WILEX: Interim management statement on the first three months of 2017 52
Mar 30, 2017: WILEX announces financial figures for the 2016 fiscal year and reports on course of business 54
Product News 56
01/24/2017: Antibody against bone marrow tumor developed at MDC is put into application 56
Product Approvals 57
Oct 20, 2017: RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer 57
Clinical Trials 58
Nov 13, 2017: Heidelberg Pharma announces results from research collaboration with Heidelberg University and the DKFZ to be presented at ASH Annual Meeting 58
Oct 19, 2017: RedHill Biopharma Announces Poster Presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 59
Sep 20, 2017: WILEX: Subsidiary Heidelberg Pharma to Present the Proprietary ATAC Technology Platform at the Annual World ADC Summit 60
Sep 18, 2017: RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering use of MESUPRON in Combination Therapy for cancers 61
Other Significant Developments 62
Oct 19, 2018: WILEX successfully completes change of name to Heidelberg Pharma 62
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63
List of Figure
List of Figures
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heidelberg Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heidelberg Pharma AG, Deals By Therapy Area, 2012 to YTD 2018 9
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Telix Pharma Enters into Licensing Agreement with Wilex 12
Magenta Therapeutics Enters into Multi-Target Research Agreement with Heidelberg Pharma 13
Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 14
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 15
Heidelberg Pharma Enters into Agreement with Celonic 16
Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 17
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 18
Magenta Therapeutics Enters into Licensing Agreement with Heidelberg Pharma 19
Heidelberg Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 20
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 21
RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 22
Wilex Enters Into Licensing Agreement With Link Health For Mesupron 23
Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 24
Wilex Raises USD5.4 Million in Rights Offering of Shares 25
Wilex to Raise USD4.7 Million in Rights Offering of Shares 26
Wilex Raises USD1.81 Million in Private Placement of Shares 27
Wilex Raises USD0.86 Million in Rights Offering of Shares 28
Wilex Raises USD4.4 Million in Right Issue of Shares 29
Wilex Completes Private Placement Of Shares For USD 12.4 Million 30
Wilex Completes Rights Offering Of Shares For USD 7.8 Million 31
Wilex Completes Rights Offering Of Shares For USD 12.6 Million 32
Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 33
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 34
Heidelberg Pharma AG, Key Competitors 35
Heidelberg Pharma AG, Key Employees 36
Heidelberg Pharma AG, Subsidiaries 37
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.